FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W968783265> ?p ?o ?g. }

• W968783265 endingPage "126" @default.
• W968783265 startingPage "122" @default.
• W968783265 abstract "Patients with transformed chronic myelogenous leukemia(CML) and advanced myelodysplastic syndrome(MDS) have poor prognosis. The aim of this study is to evaluate the feasibility of second chronic phase induction in accelerated phase(CML-AP) or blastic crisis of CML(CML-BC) and remission induction in advanced MDS by combining topoisomerase I inhibitor (topotecan) with topoisomerase II inhibitor(mitoxantrone).Twenty-four evaluable patients were entered on this study with a median age of 34 years. Eighteen patients with transformed CML(7 CML-AP, 11 CML-BC) and 6 patients with advanced MDS were treated. Topotecan was administered as 1.5 mg/m2/day by continuous infusion over 24 hours daily for 5 days every 4 to 8 weeks until remission. To enhance the tumoricidal effects, mitoxantrone(12 mg/m2/day, Days 1-3) was added.Eight patients(33%) achieved a complete remission(CR). Four of 7 patients with CML-AP(57%), 2 of 4 patients with CML-lymphoid blastic crisis (-LBC)(50%) and 2 of 6 patients with advanced MDS(33%) had CR lasting more than 45 days(45 to 400 days). There was no CR in the patients with CML-myeloid blastic crisis(-MBC). The dose level of 1.5 mg/m2/day(7.5 mg/m2/course) of topotecan was well tolerated in all patients. Mucositis occurred in 69% of patients (severe in 5%) and diarrhea in 67%(severe in 8%). In addition, there were no new or unexpected toxicities in the patients who were treated at this dose(7.5 mg/m2/course). In patients who recovered their neutrophil count, the absolute neutrophil count(ANC) remained below 500/microL for a period of 13 to 58 days(median 21 days) and the time to ANC recovery was associated with pretreatment severity of bone marrow fibrosis(mainly CML patients). Likewise, in the patients who recovered unsupported platelets, the platelets remained below 20,000/microL for a period of 0 to 37 days (median 19 days).The combination of topotecan-mitoxantrone has shown modest activity in CML-AP, CML-LBC and advanced MDS with acceptable toxicities." @default.
• W968783265 created "2016-06-24" @default.
• W968783265 creator A5013163283 @default.
• W968783265 creator A5029243528 @default.
• W968783265 creator A5043460941 @default.
• W968783265 creator A5045566016 @default.
• W968783265 creator A5060239856 @default.
• W968783265 creator A5068837815 @default.
• W968783265 creator A5071542955 @default.
• W968783265 creator A5085429434 @default.
• W968783265 date "2000-07-31" @default.
• W968783265 modified "2023-09-26" @default.
• W968783265 title "Topotecan - Based Combination Chemotherapy in Patients with Transformed Chronic Myelogenous Leukemia and Advanced Myelodysplastic Syndrome" @default.
• W968783265 cites W126102613 @default.
• W968783265 cites W146134068 @default.
• W968783265 cites W1567117625 @default.
• W968783265 cites W1832802185 @default.
• W968783265 cites W1903996452 @default.
• W968783265 cites W1952453258 @default.
• W968783265 cites W1966831567 @default.
• W968783265 cites W1995647148 @default.
• W968783265 cites W2056110230 @default.
• W968783265 cites W2102345056 @default.
• W968783265 cites W2134193067 @default.
• W968783265 cites W2167974749 @default.
• W968783265 cites W2316156427 @default.
• W968783265 cites W2346441630 @default.
• W968783265 cites W2407794389 @default.
• W968783265 cites W305459207 @default.
• W968783265 doi "https://doi.org/10.3904/kjim.2000.15.2.122" @default.
• W968783265 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4531761" @default.
• W968783265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10992724" @default.
• W968783265 hasPublicationYear "2000" @default.
• W968783265 type Work @default.
• W968783265 sameAs 968783265 @default.
• W968783265 citedByCount "1" @default.
• W968783265 crossrefType "journal-article" @default.
• W968783265 hasAuthorship W968783265A5013163283 @default.
• W968783265 hasAuthorship W968783265A5029243528 @default.
• W968783265 hasAuthorship W968783265A5043460941 @default.
• W968783265 hasAuthorship W968783265A5045566016 @default.
• W968783265 hasAuthorship W968783265A5060239856 @default.
• W968783265 hasAuthorship W968783265A5068837815 @default.
• W968783265 hasAuthorship W968783265A5071542955 @default.
• W968783265 hasAuthorship W968783265A5085429434 @default.
• W968783265 hasBestOaLocation W9687832651 @default.
• W968783265 hasConcept C126322002 @default.
• W968783265 hasConcept C2776694085 @default.
• W968783265 hasConcept C2776960273 @default.
• W968783265 hasConcept C2778461978 @default.
• W968783265 hasConcept C2778496288 @default.
• W968783265 hasConcept C2780007613 @default.
• W968783265 hasConcept C2780817109 @default.
• W968783265 hasConcept C2780923524 @default.
• W968783265 hasConcept C2781209748 @default.
• W968783265 hasConcept C71924100 @default.
• W968783265 hasConcept C90924648 @default.
• W968783265 hasConceptScore W968783265C126322002 @default.
• W968783265 hasConceptScore W968783265C2776694085 @default.
• W968783265 hasConceptScore W968783265C2776960273 @default.
• W968783265 hasConceptScore W968783265C2778461978 @default.
• W968783265 hasConceptScore W968783265C2778496288 @default.
• W968783265 hasConceptScore W968783265C2780007613 @default.
• W968783265 hasConceptScore W968783265C2780817109 @default.
• W968783265 hasConceptScore W968783265C2780923524 @default.
• W968783265 hasConceptScore W968783265C2781209748 @default.
• W968783265 hasConceptScore W968783265C71924100 @default.
• W968783265 hasConceptScore W968783265C90924648 @default.
• W968783265 hasIssue "2" @default.
• W968783265 hasLocation W9687832651 @default.
• W968783265 hasLocation W9687832652 @default.
• W968783265 hasLocation W9687832653 @default.
• W968783265 hasLocation W9687832654 @default.
• W968783265 hasOpenAccess W968783265 @default.
• W968783265 hasPrimaryLocation W9687832651 @default.
• W968783265 hasRelatedWork W1970161464 @default.
• W968783265 hasRelatedWork W1973052004 @default.
• W968783265 hasRelatedWork W1977604322 @default.
• W968783265 hasRelatedWork W1981920314 @default.
• W968783265 hasRelatedWork W2032281818 @default.
• W968783265 hasRelatedWork W2039384759 @default.
• W968783265 hasRelatedWork W2062798712 @default.
• W968783265 hasRelatedWork W2154932346 @default.
• W968783265 hasRelatedWork W2415517585 @default.
• W968783265 hasRelatedWork W2536327780 @default.
• W968783265 hasRelatedWork W2548587676 @default.
• W968783265 hasRelatedWork W2555005495 @default.
• W968783265 hasRelatedWork W2567298681 @default.
• W968783265 hasRelatedWork W2577770511 @default.
• W968783265 hasRelatedWork W2586292908 @default.
• W968783265 hasRelatedWork W2763458306 @default.
• W968783265 hasRelatedWork W2769884731 @default.
• W968783265 hasRelatedWork W2801418858 @default.
• W968783265 hasRelatedWork W2909642323 @default.
• W968783265 hasRelatedWork W3031777054 @default.
• W968783265 hasVolume "15" @default.
• W968783265 isParatext "false" @default.
• W968783265 isRetracted "false" @default.

• next